Navigation Links
Winners of WuXi PharmaTech Awards Inducted into Prestigious Academies

SHANGHAI, Dec. 23, 2013 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, congratulates five winners of the WuXi PharmaTech Life Science and Chemistry Awards on their inductions as new members of the highly prestigious Chinese Academy of Sciences (CAS) and Chinese Academy of Engineering (CAE).

CAS inducted four former WuXi award winners: Professors Jiahuai Han of Xiamen University (2009 award winner), Xiaoming Feng of Sichuan University (2010 award winner), George Fu Gao of the Institute of Microbiology at the CAS (2011 award winner), and Jie He of the Oncology Hospital at the Chinese Academy of Medical Sciences (2011 award winner). Professor Guangji Wang of China Pharmaceutical University (2008 award winner) was inducted into the CAE.

The WuXi PharmaTech Life Science and Chemistry Awards are the first nationwide scientific award in China established by a life science enterprise with the mission of fostering early innovation and encouraging the pursuit of excellence in the life sciences. Eight of the 95 scholars awarded between the awards' inception in 2007 and 2012 were later elected to the CAS or the CAE.

"We are proud to see the excellent work of five of our former award winners recognized by the CAS and the CAE," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "Their groundbreaking scientific research provides great insights into diseases and holds promise for better cures. The inductions are very well deserved."

About WuXi PharmaTech

As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi AppTec is the name for the operating subsidiaries of WuXi PharmaTech. For more information, please visit:

WuXi PharmaTech's Contacts:

Ronald Aldridge, Director of Investor Relations
+1 (201) 585-2048

Aaron Shi, Associate Director, Corporate Communications

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elsevier and Algerian Ministry of Higher Education and Research Announce the Winners of 2013 Algerian Scopus Award Winners
2. Biocom Announces 2013 DeviceFest & Expo Award Winners
3. Allscripts Announces Winners of the Open App Challenge
4. Allscripts Announces 2013 Client Excellence Award Winners
5. UBM Canon and MD+DI Proudly Announce 27 Innovative Products as Winners of the 2013 Medical Design Excellence Awards
6. 2013 Facility of the Year Awards (FOYA) Winners Announced
7. Cochlear Americas Announces 2013 Graeme Clark and Anders Tjellstrom Scholarship Winners
8. Seahorse Bioscience Announces Asia Mito 2012 Travel Award Winners Advancing Cell Metabolism Research
9. Archbishop Desmond Tutu and the International Childrens Peace Prize Winners Launch Remember2015
10. Elsevier and Australasian Research Management Society Announce Winners of the 2012 Scopus Young Researcher of the Year Awards
11. Telemedicine, Teleradiology, and Telemonitoring Look Like Winners in the New Healthcare Economy
Post Your Comments:
(Date:12/1/2015)... 2015 Breg, Inc ., a premier ... that it has been awarded three contracts by Novation, ... Novation will have access to improved pricing for Breg,s ... soft goods dedicated to advancing orthopedic care.  ... U.S. population, rising prevalence of chronic conditions and the ...
(Date:12/1/2015)... , December 1, 2015 Russia ... III clinical trials. 70% of new drugs registered in Europe ... in Russia . --> Russia has always ... 70% of new drugs registered in Europe in ... --> Russia has always been a ...
(Date:12/1/2015)... 1, 2015 CytRx Corporation (NASDAQ: CYTR ... oncology, today announced that it has reached its enrollment ... Phase 3 clinical trial of aldoxorubicin in patients with ... to be completed in Q1 2016. The Phase 3 trial ... Special Protocol Assessment from the FDA at 79 sites ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... , ... Integrated Rental Services (“Integrated Rental”), a growing medical ... , With support from JII, Integrated Rental is poised for expansion while improving ... research labs and medical facilities across the United States. , General Manager Robert ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Califia ... today announced that its iconic bottle has won top honors in Beverage World Magazine’s ... The Company also announced that it has been selected as a 2015 U.S.A. Taste ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... we have seen vast improvements in scientific research and discoveries, leading us to ... increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform edition of ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of ... is the focus of numerous abstracts accepted for presentation here, at the 101st ... Nine abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
Breaking Medicine News(10 mins):